CYP2C9 Polymorphisms and the Risk of Cardiovascular Events in Patients Treated with Clopidogrel: Combined Data from the POPular Genetics and POPular AGE Trials.
Wout W A van den BroekNabil ManiJaouad AzzahhafiJurrien M Ten BergPublished in: American journal of cardiovascular drugs : drugs, devices, and other interventions (2023)
Carriers of a CYP2C9 *2 or *3 LoF allele presenting with acute coronary syndrome and treated with clopidogrel did not have an increased risk for thrombotic events compared with noncarriers. Given the limited number of poor metabolizers, no firm conclusions could be drawn with regard to the thrombotic risk for patients carrying two CYP2C9 LoF alleles.
Keyphrases
- acute coronary syndrome
- cardiovascular events
- percutaneous coronary intervention
- antiplatelet therapy
- end stage renal disease
- newly diagnosed
- coronary artery disease
- ejection fraction
- cardiovascular disease
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- electronic health record
- patient reported outcomes
- big data
- atrial fibrillation
- data analysis